



## Novel Drugs, Targets and Therapies against Infectious Diseases

Guest Editors:

### Dr. Eva Torres-Sangiao

Clinical Microbiology Laboratory,  
University Hospital Marqués de  
Valdecilla, Research Institute  
IDIVAL, 39001 Santander, Spain

### Dr. Erkki O. Ylösmäki

1. Director, Research and  
Development Rokote  
Laboratories Finland Oy, 00014  
Helsinki, Finland  
2. Adjunct Professor, Faculty of  
Pharmacy, University of Helsinki,  
00014 Helsinki, Finland

Deadline for manuscript  
submissions:

**30 April 2024**

### Message from the Guest Editors

Currently, the treatment of infectious diseases has become substantially complicated and is therefore a serious problem in health and disease management. The increase in drug resistance, as well as the threat of new pandemics and emerging infections is a fact. This necessitates the development of new strategies, improved conventional antimicrobials drugs, or even completely new mechanisms of action. In fact, bioinformatics methods such as molecular dynamics, molecular docking or QSAR (including in silico methods) are strategically used when new drugs are considered for potential use, e.g., for SARS-CoV-2 infection.

This Special Issue on “Novel Drugs, Targets, and Therapies against Infectious Diseases” focuses on the identification and further optimization of corresponding compounds and strategies, for example, i) target-, ligand-, and computer-based approaches that involve biological evaluation, ii) drug design and drug formulation/delivery, and iii) molecular docking, molecular dynamics. Interdisciplinary studies are encouraged for submission.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,  
Ernest Mario School of  
Pharmacy, Rutgers University,  
Piscataway, NJ 08854, USA

## Message from the Editor-in-Chief

*Pharmaceutics* (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*Pharmaceutical Science*)

## Contact Us

*Pharmaceutics* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceutics](http://mdpi.com/journal/pharmaceutics)  
[pharmaceutics@mdpi.com](mailto:pharmaceutics@mdpi.com)  
X@MDPIpharma